Resource Type

Journal Article 4

Year

2023 1

2016 2

2009 1

Keywords

CYP2J2 1

MID2 1

atorvastatin 1

benzydamine 1

breast cancer 1

co-clinical trial 1

cyclin-dependent kinase 2 1

esophageal squamous cell carcinoma 1

metastasis 1

oral squamous cell carcinoma 1

overall survival 1

patient stratification 1

patient-derived xenograft 1

patient-derived xenograft models 1

personalized medicine 1

proliferation 1

xenograft 1

xenograft tumor 1

open ︾

Search scope:

排序： Display mode:

Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research

Shuyang Sun,Zhiyuan Zhang

Frontiers of Medicine 2016, Volume 10, Issue 1,   Pages 104-110 doi: 10.1007/s11684-016-0432-4

Abstract: Patient-derived xenograft (PDX) models generated from human tumor samples that can retain the histological

Keywords： patient-derived xenograft models     personalized medicine     co-clinical trial     patient stratification     oral    

HTML PDF Collect

Effect of atorvastatin on tumor growth and metastasis in a breast cancer cell xenograft model and its

Liu LIU MD, PhD, Yaogui NING MM, Chen CHEN MD, Daowen WANG MD, PhD,

Frontiers of Medicine 2009, Volume 3, Issue 4,   Pages 443-446 doi: 10.1007/s11684-009-0079-5

Abstract: evaluate the effects and the possible mechanisms of atorvastatin on tumor growth and metastasis in a xenograftTwenty-four female athymic BALB/C mice with MDA-MB-435 xenograft tumors were randomly assigned to threetreatment groups began to be administered with atorvastatin (10 or 20 mg/kg per day) when the xenograftAtorvastatin suppressed xenograft tumor growth and metastasis both in the low-dose and the high-dose

Keywords： atorvastatin     xenograft tumor     metastasis     CYP2J2    

HTML PDF Collect

Repurposed benzydamine targeting CDK2 suppresses the growth of esophageal squamous cell carcinoma

Frontiers of Medicine 2023, Volume 17, Issue 2,   Pages 290-303 doi: 10.1007/s11684-022-0956-8

Abstract: Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer death worldwide. It is urgent to develop new drugs to improve the prognosis of ESCC patients. Here, we found benzydamine, a locally acting non-steroidal anti-inflammatory drug, had potent cytotoxic effect on ESCC cells. Benzydamine could suppress ESCC proliferation in vivo and in vitro. In terms of mechanism, CDK2 was identified as a target of benzydamine by molecular docking, pull-down assay and in vitro kinase assay. Specifically, benzydamine inhibited the growth of ESCC cells by inhibiting CDK2 activity and affecting downstream phosphorylation of MCM2, c-Myc and Rb, resulting in cell cycle arrest. Our study illustrates that benzydamine inhibits the growth of ESCC cells by downregulating the CDK2 pathway.

Keywords： benzydamine     cyclin-dependent kinase 2     patient-derived xenograft     esophageal squamous cell carcinoma    

HTML PDF Collect

Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer cell proliferation in vitro and in vivo

Lan Wang,Jueheng Wu,Jie Yuan,Xun Zhu,Hongmei Wu,Mengfeng Li

Frontiers of Medicine 2016, Volume 10, Issue 1,   Pages 41-51 doi: 10.1007/s11684-016-0429-z

Abstract: reduced MCF-7 and MDA-MB-231 cell proliferation in vitro and blocked the growth of MDA-MB-231 cell xenograft

Keywords： breast cancer     MID2     proliferation     overall survival     xenograft    

HTML PDF Collect

Title Author Date Type Operation

Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research

Shuyang Sun,Zhiyuan Zhang

Journal Article

Effect of atorvastatin on tumor growth and metastasis in a breast cancer cell xenograft model and its

Liu LIU MD, PhD, Yaogui NING MM, Chen CHEN MD, Daowen WANG MD, PhD,

Journal Article

Repurposed benzydamine targeting CDK2 suppresses the growth of esophageal squamous cell carcinoma

Journal Article

Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer cell proliferation in vitro and in vivo

Lan Wang,Jueheng Wu,Jie Yuan,Xun Zhu,Hongmei Wu,Mengfeng Li

Journal Article